Even when depression drugs address known and validated targets, their commercial potential can be constrained by dosing or safety limitations. Seaport Therapeutics’ drugs use a novel delivery approach ...

While all Resolutions were passed with significant majorities, the Board notes that Resolutions 2 and 9 received less than 80% of votes cast in favor. The Board has consistently taken steps to ...

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December ...

PureTech Health(NASDAQ:PRTC) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in ...

(RTTNews) - Clinical-stage biotherapeutics company PureTech Health plc (PRTC, PRTC.L) reported Wednesday that its first-half loss before tax widened to $55.03 million from last year's loss of $13.74 ...

Maintained a strong financial position with $319.6M PureTech level cash, cash equivalents and short-term investments and $319.9M Consolidated cash, cash equivalents and short-term investments as of ...

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused ...

PureTech Health plc (NASDAQ:PRTC) stock is up on Monday, after the company announced results from ELEVATE IPF Phase 2b trial of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF). The ...

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Monday, June 16, 2025. All of the resolutions ...

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and ...